Back to top

Analyst Blog

Zacks Equity Research

AstraZeneca and NGM Collaborate

AZN SLXP

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

AstraZeneca (AZN - Analyst Report) recently announced that MedImmune (the biologics research and development arm of AstraZeneca) has entered into an agreement with privately-held US-based company, NGM Biopharmaceuticals, Inc. for discovery, development and commercialization of candidates from NGM Biopharma’s enteroendocrine cell (EEC) program. Together, the companies will develop candidates for type II diabetes and obesity.

As per the terms of the agreement, NGM Biopharma will receive an upfront payment and will be eligible to receive milestone payments subject to achievement of certain development, regulatory and commercial targets from AstraZeneca. AstraZeneca will also provide research funding and pay royalties on net sales of the products arising from this agreement.

We note generic competition has adversely impacted AstraZeneca’s revenues over the past few quarters. This has put significant pressure on the company. AstraZeneca is looking to combat generic erosion faced by many of its key drugs by signing deals, making acquisitions and developing new products.

Its agreements with Karolinska Institutet (to conduct preclinical and clinical trials for candidates targeting cardiovascular and metabolic diseases), Moderna Therapeutics (to develop RNA therapeutics for the treatment of serious cardiovascular, metabolic and renal diseases and cancer) and BIND Therapeutics (for development and commercialization cancer nanomedicine) are efforts in that direction.

AstraZeneca entered into a number acquisition deals including Pearl Therapeutics, Omthera Pharmaceuticals, Inc. and AlphaCore Pharma in the last few months.

AstraZeneca carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. and Salix Pharmaceuticals (SLXP - Analyst Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%